Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle

François Lamoureux, Marc Baud’huin, Lidia Rodriguez Calleja, Camille Jacques, Martine Berreur, Françoise Rédini, Fernando Lecanda, James E. Bradner, Dominique Heymann and Benjamin Ory ()
Additional contact information
François Lamoureux: INSERM, UMR 957, Équipe labellisée ligue 2012, 1 Rue Gaston Veil
Marc Baud’huin: INSERM, UMR 957, Équipe labellisée ligue 2012, 1 Rue Gaston Veil
Lidia Rodriguez Calleja: INSERM, UMR 957, Équipe labellisée ligue 2012, 1 Rue Gaston Veil
Camille Jacques: INSERM, UMR 957, Équipe labellisée ligue 2012, 1 Rue Gaston Veil
Martine Berreur: INSERM, UMR 957, Équipe labellisée ligue 2012, 1 Rue Gaston Veil
Françoise Rédini: INSERM, UMR 957, Équipe labellisée ligue 2012, 1 Rue Gaston Veil
Fernando Lecanda: Adhesion and Metastasis Laboratory, Center for Applied Medical Research (CIMA), University of Navarra, Pio XII-55
James E. Bradner: Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street
Dominique Heymann: INSERM, UMR 957, Équipe labellisée ligue 2012, 1 Rue Gaston Veil
Benjamin Ory: INSERM, UMR 957, Équipe labellisée ligue 2012, 1 Rue Gaston Veil

Nature Communications, 2014, vol. 5, issue 1, 1-14

Abstract: Abstract The vicious cycle established between bone-associated tumours and bone resorption is the central problem with therapeutic strategies against primary bone tumours and bone metastasis. Here we report data to support inhibition of BET bromodomain proteins as a promising therapeutic strategy that target simultaneously the three partners of the vicious cycle. Treatment with JQ1, a BET bromodomain inhibitor, reduces cell viability of osteosarcoma cells and inhibits osteoblastic differentiation both in vitro and in vivo. These effects are associated with transcriptional silencing of MYC and RUNX2, resulting from the depletion of BRD4 from their respective loci. Moreover, JQ1 also inhibits osteoclast differentiation by interfering with BRD4-dependent RANKL activation of NFATC1 transcription. Collectively, our data indicate that JQ1 is a potent inhibitor of osteoblast and osteoclast differentiation as well as bone tumour development.

Date: 2014
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/ncomms4511 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:5:y:2014:i:1:d:10.1038_ncomms4511

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms4511

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().